News

Next Generation Vaccines: Adjuvants and delivery systems

Off

Monday, 20 October 2014

Cineworld: The O2, London, SE10 0DX, UK

www.regonline.co.uk/vacc2014

This event will discuss current research into the development of new or enhanced adjuvants and novel delivery systems which are widely accepted as key to creating more efficacious vaccines with improved methods for storage and delivery.

This event has CPD accreditation and is part of  Vaccines 2014. Oct 20th -22nd, LONDON, UK

www.vaccines2014.com

The deadline for abstract submissions for oral presentation is August 10th 2014

Abstracts for poster presentation only can be submitted up to two weeks before the event. You can download the instructions for authors at

www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf

 Talks Include

  • Optimizing delivery of next generation immune potentiators: Dr Manmohan Singh, Novartis Vaccines, North Carolina, USA
  • Tubular immunostimulating complex based on glycolipid and saponin from marine hydrobiont: Professor Nina Sanina, Far Eastern Federal University, Russia
  • The Next Generation of Vaccines, Adjuvants, and Delivery Systems: Lessons from the Past 50 Years:  Dr Lawrence Dean Frenkel, Professor, Departments of Pediatrics and Microbiology, University of Illinois, USA
  • DNA Vaccination Encoding CD40 Targeted to Dendritic Cells Protects Against Chronic Kidney Disease:  Dr Yuan Min Wang, Senior Scientist, Senior Lecturer, University of Sydney Renal Laboratory, Centre for Kidney Research, Australia

Additional confirmed Speakers

  • Professor Talin Barisani-Asenbauer, Scientific Director, OCUVAC – Centre of Ocular Inflammation and Infection, Medical University of Vienna, Austria
  • Professor Yvonne Perrie, Aston University, Birmingham, UK
  • Professor Nikolai Petrovsky, Flinders Medical Centre, Adelaide, Australia

 www.regonline.co.uk/vacc2014

Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: https://developer.twitter.com/en/portal/product